Mariella Lilue *

Autor invitado por SIIC

USO DE LA DESVENLAFAXINA PARA SINTOMAS VASOMOTORES

LA PRIMERA LINEA DE TRATAMIENTO PARA LOS SINTOMAS VASOMOTORES EN LA TERAPIA HORMONAL, SIN EMBARGO PARA CASOS ESPECIFICOS , EL INHIBIDOR SELECTIVO DE LA RECAPTACION DE SEROTONINA Y NORADRENALINA , LA DESVENLAFAXINA, ES UNA ALTERNATIVA NO HORMONAL PARA EL TRATAMIENTO DE LOS SINTOMAS VASOMOTORES, QUE HA DEMOSTRADO EFICACIA TANTO EN EL CONTROL COMO EN LA DISMINUCION DE LOS MISMOS EN UN 60%.

*Mariella Lilue
describe para SIIC los aspectos relevantes de su trabajo
NON-HORMONAL TREATMENT FOR VASOMOTOR SYMPTOMS DURING MENOPAUSE: ROLE OF DESVENLAFAXINE
Institución principal de la investigación
*Instituto Palacios de Salud y Medicina de la Mujer, Madrid, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1- Gold E.B; Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J epidemiol 2000; 152 (5): 463-73

2- The North American Menopause Society. Treatment of menopause –associated vasomotor symptoms: position statement of the North America Menopause Society, menopause 2004;11 (1):11-33

3- Freedman R. Hot flashes: behavioural treatments, mechanism and relation to sllep. Am J Med 2005; 118(12B): 124s-130s

4- Deecher D. Fisiologia de la function termorreguladora y enfoques actuals del tratamiento de los sintomas vasomotores. Expert Opin 2005. Invest Drug 2005;14 (4):435-48

5- Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for the treatment of hot flashes . J Clin Oncol 2002;20(6): 1578-83

6- Stearns B, beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treaetment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289(21): 2827-34

7- Alfinito P, Huselton C, Chen X, Deecher D. Pharmacokinetic and pharmacodinamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brainm research 2006; 1098: 71-78

8- DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind , placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of mayor depressive disorder. J Clin Psychiatry 2007; 68(5):677-88

9- Septien-Velez L, pitrosky B, Padmanabhan SK, germain JM, Tourian KA, A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of mayor depressive disorder. Int Clin Psychopharmacol 2007; 22 (6): 338-47

10- Liebowitz MR, Yeunmg PP, Entsuah R. A randomized, doble-blind, placebo controlled trial of desvenlafaxine succinate in adult outpatients with mayor depressive disorders. J Clin Psiquiatry 2007; 68/11): 1663-72

11- Feiger Ad, Tourian KA, Rosas GR, Padmanabhan SK. A placebo controlled study evaluating the efficacy and safety of flexible dose desvenlafaxine treatment in outpatients with mayor depresive disorder CNS Spectr 2009; 14(1): 41-50

12- Lieberman DZ, Montgomery SA, Tourian KA et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in mayor depressive disorder. Int Clin Psycopharmacol 2008; 23(4):188-97

13- Speroff L, Margery G, Ginger C, Oliver S. efficacy and tolerability of desvenlafaxine succinate treatment for menopausal Vasomotor Symptoms. Obstet Gynecol 2008;111(1): 77-86

14- Archer D, Dupont C, Ginger C, Pickard J, Olvier S. desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind , randomized placebo-controlled trial of efficacy and safety . Am J Obst and Gynecol 2009, 238:e1-238e10.

15- Archer D , Seidman L, Constantine G, Pickar J, Olivier S. A doublé-blind, randomly assigned, placebo controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 172: e1-172 e 10.